JP2022548690A - Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 - Google Patents
Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 Download PDFInfo
- Publication number
- JP2022548690A JP2022548690A JP2022517374A JP2022517374A JP2022548690A JP 2022548690 A JP2022548690 A JP 2022548690A JP 2022517374 A JP2022517374 A JP 2022517374A JP 2022517374 A JP2022517374 A JP 2022517374A JP 2022548690 A JP2022548690 A JP 2022548690A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- compound
- heterocyclyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193094A JP7781244B2 (ja) | 2019-09-20 | 2024-11-01 | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962903438P | 2019-09-20 | 2019-09-20 | |
| US62/903,438 | 2019-09-20 | ||
| PCT/US2020/051486 WO2021055744A1 (en) | 2019-09-20 | 2020-09-18 | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193094A Division JP7781244B2 (ja) | 2019-09-20 | 2024-11-01 | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022548690A true JP2022548690A (ja) | 2022-11-21 |
| JPWO2021055744A5 JPWO2021055744A5 (enExample) | 2023-09-20 |
Family
ID=72744866
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517374A Ceased JP2022548690A (ja) | 2019-09-20 | 2020-09-18 | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
| JP2024193094A Active JP7781244B2 (ja) | 2019-09-20 | 2024-11-01 | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193094A Active JP7781244B2 (ja) | 2019-09-20 | 2024-11-01 | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220389003A1 (enExample) |
| EP (1) | EP4031249A1 (enExample) |
| JP (2) | JP2022548690A (enExample) |
| KR (1) | KR20220066922A (enExample) |
| CN (1) | CN114555593A (enExample) |
| AU (1) | AU2020348489A1 (enExample) |
| BR (1) | BR112022004624A2 (enExample) |
| CA (1) | CA3147493A1 (enExample) |
| IL (1) | IL291436A (enExample) |
| MX (1) | MX2022003276A (enExample) |
| TW (1) | TWI873187B (enExample) |
| WO (1) | WO2021055744A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| EP4413000A1 (en) | 2021-10-04 | 2024-08-14 | FoRx Therapeutics AG | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| AU2022359801A1 (en) | 2021-10-04 | 2024-02-01 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2023154913A1 (en) * | 2022-02-14 | 2023-08-17 | Arase Therapeutics Inc. | Inhibitors of parg |
| JP2025509180A (ja) * | 2022-03-04 | 2025-04-11 | 上海瓔黎薬業有限公司 | 五員ヘテロアリール環構造含有化合物、その医薬組成物及び使用 |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023183850A1 (en) * | 2022-03-23 | 2023-09-28 | Ideaya Biosciences, Inc. | Piperazine substituted indazole compounds as inhibitors of parg |
| CN117157299B (zh) * | 2022-04-28 | 2024-05-28 | 北京丹擎医药科技有限公司 | 三环杂环衍生物及其组合物和应用 |
| WO2023224998A1 (en) * | 2022-05-17 | 2023-11-23 | 858 Therapeutics, Inc. | Inhibitors of parg |
| JP2025522274A (ja) | 2022-05-17 | 2025-07-15 | ８５８ セラピューティクス，インコーポレーテッド | Ｐａｒｇの阻害剤 |
| WO2024002284A1 (zh) * | 2022-06-29 | 2024-01-04 | 杭州圣域生物医药科技有限公司 | 五元并六元含氮化合物、其中间体、制备方法和应用 |
| EP4559912A1 (en) * | 2022-07-19 | 2025-05-28 | Evopoint Biosciences Co., Ltd. | Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof, and use thereof |
| EP4311829A1 (en) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer |
| WO2024074497A1 (en) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Parg inhibitory compound |
| JP2025533274A (ja) * | 2022-10-13 | 2025-10-03 | ハンミ ファーマシューティカルズ カンパニー リミテッド | Ｙａｐ－ｔｅａｄ相互作用を阻害するための新規なヘテロ二環式化合物及びそれを含む薬学的組成物 |
| WO2024148280A1 (en) | 2023-01-06 | 2024-07-11 | Ideaya Biosciences, Inc. | Treatment of er+ breast cancer comprising homologous recombination deficiency using parc inhibitor |
| WO2024173234A1 (en) * | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2024173530A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted pyrazolo/imidazo pyridine compounds |
| WO2024173524A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted benzimidazole compounds |
| WO2024173453A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted imidazopyridine compounds |
| WO2024173514A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Amide and ester-substituted imidazopyridine compounds |
| WO2024209035A1 (en) | 2023-04-05 | 2024-10-10 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2024211506A1 (en) | 2023-04-05 | 2024-10-10 | Ideaya Biosciences, Inc. | Combination therapy comprising a parg inhibitor and a topoisomerase inhibitor for treating cancer |
| CN121002021A (zh) * | 2023-04-27 | 2025-11-21 | 北京丹擎医药科技有限公司 | 三环杂环衍生物及其组合物和应用 |
| CN119143747A (zh) * | 2023-06-16 | 2024-12-17 | 上海璎黎药业有限公司 | 一种杂芳环结构化合物、其药物组合物及应用 |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| TW202528308A (zh) * | 2023-09-20 | 2025-07-16 | 美商愛德亞生物科學公司 | Parg抑制劑 |
| WO2025064750A1 (en) | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| WO2025072544A1 (en) * | 2023-09-27 | 2025-04-03 | Ideaya Biosciences, Inc. | Sulfonamino indazole compounds as inhibitors of parg |
| CN119708015A (zh) * | 2023-09-28 | 2025-03-28 | 杭州圣域生物医药科技有限公司 | 杂芳基化合物、其中间体、制备方法和应用 |
| WO2025073870A1 (en) | 2023-10-03 | 2025-04-10 | Forx Therapeutics Ag | Parg inhibitory compound |
| CN119859145A (zh) * | 2023-10-20 | 2025-04-22 | 上海璎黎药业有限公司 | 一种杂芳环磺酰胺结构化合物、其药物组合物及应用 |
| WO2025087941A1 (en) | 2023-10-23 | 2025-05-01 | Universite De Geneve | Parg inhibitors in combination with parp inhibitors and uses thereof |
| TW202523299A (zh) * | 2023-10-26 | 2025-06-16 | 大陸商上海齊魯製藥研究中心有限公司 | Parg抑制劑 |
| WO2025093755A1 (en) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Novel parc inhibitors |
| WO2025098445A1 (zh) * | 2023-11-07 | 2025-05-15 | 南京同诺康医药科技有限公司 | Parg抑制剂及其制备方法和用途 |
| WO2025108225A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海复星医药（集团）股份有限公司 | 作为parg抑制剂的含氮三环衍生物 |
| WO2025111339A1 (en) * | 2023-11-21 | 2025-05-30 | 858 Therapeutics, Inc. | Treatment of cancer with a parg inhibitor |
| TW202529739A (zh) * | 2023-11-22 | 2025-08-01 | 美商858療法股份有限公司 | Parg之抑制劑 |
| WO2025133396A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Novel bicyclo heteroaryl parg inhibitors |
| WO2025133191A1 (en) * | 2023-12-22 | 2025-06-26 | Genecode | Novel sulfonamides or sulfones and their use as neuroprotective and/or neurorestorative agents |
| WO2025229549A1 (en) * | 2024-04-30 | 2025-11-06 | Satyarx Pharma Innovations Pvt Ltd | Novel heterocyclic compounds as inhibitors of parg |
| CN118459452B (zh) * | 2024-07-10 | 2024-10-25 | 苏州国匡医药科技有限公司 | 一种多聚adp核糖水解酶抑制剂及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012093707A1 (ja) * | 2011-01-07 | 2012-07-12 | 大鵬薬品工業株式会社 | 新規インドール、インダゾール誘導体又はその塩 |
| JP2017537137A (ja) * | 2014-12-12 | 2017-12-14 | キャンサー リサーチ テクノロジー リミティド | Ｐａｒｇの阻害剤としての２，４−ジオキソ−キナゾリン−６−スルホンアミド誘導体 |
| JP2017538750A (ja) * | 2014-12-19 | 2017-12-28 | キャンサー リサーチ テクノロジー リミティド | Ｐａｒｇ阻害化合物 |
| WO2019079369A1 (en) * | 2017-10-19 | 2019-04-25 | Effector Therapeutics, Inc. | BENZIMIDAZOLE INDOLE INHIBITORS OF MNK1 AND MNK2 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| RU2003103603A (ru) | 2000-07-07 | 2004-08-20 | Энджиоджен Фармасьютикалз Лимитед (Gb) | Производные колхинола в качестве ингибиторов ангиогенеза |
| EP3870575B1 (en) * | 2018-10-25 | 2023-03-29 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2023183850A1 (en) * | 2022-03-23 | 2023-09-28 | Ideaya Biosciences, Inc. | Piperazine substituted indazole compounds as inhibitors of parg |
-
2020
- 2020-09-18 CN CN202080065861.1A patent/CN114555593A/zh active Pending
- 2020-09-18 KR KR1020227012903A patent/KR20220066922A/ko active Pending
- 2020-09-18 US US17/761,935 patent/US20220389003A1/en active Pending
- 2020-09-18 MX MX2022003276A patent/MX2022003276A/es unknown
- 2020-09-18 TW TW109132483A patent/TWI873187B/zh active
- 2020-09-18 EP EP20786137.8A patent/EP4031249A1/en active Pending
- 2020-09-18 AU AU2020348489A patent/AU2020348489A1/en active Pending
- 2020-09-18 WO PCT/US2020/051486 patent/WO2021055744A1/en not_active Ceased
- 2020-09-18 BR BR112022004624A patent/BR112022004624A2/pt unknown
- 2020-09-18 CA CA3147493A patent/CA3147493A1/en active Pending
- 2020-09-18 JP JP2022517374A patent/JP2022548690A/ja not_active Ceased
-
2022
- 2022-03-16 IL IL291436A patent/IL291436A/en unknown
-
2024
- 2024-11-01 JP JP2024193094A patent/JP7781244B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012093707A1 (ja) * | 2011-01-07 | 2012-07-12 | 大鵬薬品工業株式会社 | 新規インドール、インダゾール誘導体又はその塩 |
| JP2017537137A (ja) * | 2014-12-12 | 2017-12-14 | キャンサー リサーチ テクノロジー リミティド | Ｐａｒｇの阻害剤としての２，４−ジオキソ−キナゾリン−６−スルホンアミド誘導体 |
| JP2017538750A (ja) * | 2014-12-19 | 2017-12-28 | キャンサー リサーチ テクノロジー リミティド | Ｐａｒｇ阻害化合物 |
| WO2019079369A1 (en) * | 2017-10-19 | 2019-04-25 | Effector Therapeutics, Inc. | BENZIMIDAZOLE INDOLE INHIBITORS OF MNK1 AND MNK2 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220389003A1 (en) | 2022-12-08 |
| TWI873187B (zh) | 2025-02-21 |
| TW202120501A (zh) | 2021-06-01 |
| IL291436A (en) | 2022-05-01 |
| MX2022003276A (es) | 2022-04-11 |
| CN114555593A (zh) | 2022-05-27 |
| CA3147493A1 (en) | 2021-03-25 |
| WO2021055744A1 (en) | 2021-03-25 |
| EP4031249A1 (en) | 2022-07-27 |
| AU2020348489A1 (en) | 2022-05-05 |
| JP2025016684A (ja) | 2025-02-04 |
| BR112022004624A2 (pt) | 2022-05-31 |
| JP7781244B2 (ja) | 2025-12-05 |
| KR20220066922A (ko) | 2022-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7781244B2 (ja) | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 | |
| KR102616970B1 (ko) | Ｐｒｍｔ５-매개성 질환의 치료 또는 예방에 유용한 화합물 | |
| EP3630749B1 (en) | 2-quinolone derived inhibitors of bcl6 | |
| US11274098B2 (en) | Tricyclic compounds for use in treatment of proliferative disorders | |
| WO2021003314A1 (en) | Heterocyclic compounds as kinase inhibitors | |
| WO2024173453A1 (en) | Heteroaryl-substituted imidazopyridine compounds | |
| WO2024173524A1 (en) | Heteroaryl-substituted benzimidazole compounds | |
| AU2018291687B2 (en) | New quinolinone compounds | |
| EP3481824A1 (en) | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity | |
| BR112020010012A2 (pt) | compostos de pirazolopiridinona | |
| WO2024173514A1 (en) | Amide and ester-substituted imidazopyridine compounds | |
| WO2014160177A2 (en) | Quinazoline inhibitors of pi3k | |
| WO2024173530A1 (en) | Heteroaryl-substituted pyrazolo/imidazo pyridine compounds | |
| RU2827549C2 (ru) | Соединения тиенопиридинона | |
| EP4584267A1 (en) | Novel compounds as ck2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220705 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230911 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230911 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240815 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240903 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241003 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20250128 |